Long-lasting birth control delivered to her door

Annovera®
(segesterone acetate and ethinyl estradiol vaginal system)
Delivers 0.15 mg/0.013 mg per day

Provide her with birth control that she controls during the COVID-19 crisis and beyond.

- **Procedure-free, reversible contraception** as ACOG recommends: "If provision of LARC methods or permanent contraception is unavailable during this pandemic: offer contraceptives that can be self-administered as a bridge to delayed insertion."[1]
- **Annual* contraception, with one prescription,** during this time of economic uncertainty with the potential loss of health insurance

ANNOVERA is the only **long-lasting** contraceptive that is **patient-controlled** and **procedure-free**[2]

	Annovera®	IUDs	IMPLANTS	OTHER COMBINATION HORMONAL CONTRACEPTIVES
Patient-controlled	✓			✓
Procedure-free	✓			✓
Long-lasting	✓	✓	✓	

*ANNOVERA is inserted for 21 continuous days and removed for 7 days for one year (13 cycles)
†Based on pharmacological studies in animals and in vitro studies. The clinical significance of these data is not known.

- **Empowers women** to be in control of both their **fertility** and **menstruation***
- Novel hormone profile - ANNOVERA releases a **non-androgenic progestin** and **one of the lowest doses** of ethinyl estradiol (13 mcg) daily[2,3†]

You can get patients started on ANNOVERA without an office visit
Prescribe ANNOVERA today

ANNOVERA is currently available at all retail pharmacies, major online channels, and through vitaCare Prescription Services - **vitaCareRx.com**

IMPORTANT SAFETY INFORMATION

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
See full prescribing information for complete boxed warning.

- **Females over 35 years old who smoke should not use ANNOVERA.**
- **Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive use.**

Please see Indication and additional Important Safety Information on next page and Full Prescribing Information, including BOXED WARNING, at ANNOVERA.com/pi.pdf

CONTRAINDICATIONS

ANNOVERA is contraindicated and should not be used in women with a high risk of arterial or venous thrombotic diseases; current or history of breast cancer or other estrogen- or progestin-sensitive cancer; liver tumors, acute hepatitis, or severe (decompensated) cirrhosis; undiagnosed abnormal uterine bleeding; hypersensitivity to any of the components of ANNOVERA; and use of Hepatitis C drug combinations containing ombitasvir/partaprevir/ritonavir, with or without dasabuvir.

WARNINGS AND PRECAUTIONS

- Stop ANNOVERA if a thrombotic or thromboembolic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Start ANNOVERA no earlier than 4 weeks after delivery, in females who are not breastfeeding. Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years.
- Discontinue if jaundice occurs.
- Stop ANNOVERA prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir. ANNOVERA can be restarted 2 weeks following completion of this regimen.
- Do not prescribe ANNOVERA for females with uncontrolled hypertension or hypertension with vascular disease. Monitor blood pressure and stop use if blood pressure rises significantly in females with well-controlled hypertension.
- Monitor glucose in pre-diabetic or diabetic females taking ANNOVERA. Consider an alternate contraceptive method for females with uncontrolled dyslipidemias.
- Patients using ANNOVERA who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. ANNOVERA should be discontinued if indicated.
- Other warnings include: gallbladder disease; depression; cervical cancer; increased serum concentrations of binding globulins; hereditary angioedema; chloasma (females who tend to develop chloasma should avoid exposure to the sun or UV radiation while using ANNOVERA); toxic shock syndrome (TSS) (if a patient exhibits symptoms of TSS, remove ANNOVERA, and initiate appropriate medical treatment); vaginal use (ANNOVERA may not be suitable for females with conditions that make the vagina more susceptible to vaginal irritation or ulceration).

ADVERSE REACTIONS

The most common adverse reactions reported in at least 5% of women who received ANNOVERA were: headache/migraine, nausea/vomiting, vulvovaginal mycotic infection/candidiasis, lower/upper abdominal pain, dysmenorrhea, vaginal discharge, urinary tract infection, breast pain/tenderness/discomfort, bleeding irregularities including metrorrhagia, diarrhea, and genital pruritus.

DRUG INTERACTIONS

Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of ANNOVERA or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with ANNOVERA.

INDICATION

ANNOVERA is a progestin/estrogen combination hormonal contraceptive indicated for use by females of reproductive potential to prevent pregnancy.

Limitations of Use: ANNOVERA has not been adequately studied in females with a body mass index >29 kg/m^2.

Please note this information is not comprehensive. Please see Full Prescribing Information, including BOXED WARNING, at ANNOVERA.com/pi.pdf

References: 1. American College of Obstetricians Gynecologists. COVID-19 FAQs for Obstetricians-Gynecologists, Gynecology. Available at https://www.acog.org/clinical-information/physician-faqs/covid19-faqs-for-ob-gyns-gynecology **2.** ANNOVERA [Full Prescribing Information]. Boca Raton, FL: TherapeuticsMD, Inc; 2020. **3.** Kumar N, Koide SS, Tsong YY, Sundaram K. Nestorone: A progestin with a unique pharmacological profile. Steroids, 2000;65:629-36.

TherapeuticsMD®

For Her. For Life.

**ANNUAL.
COMFORTABLE.
CONTROLLABLE.**

Annovera®
(segesterone acetate and ethinyl estradiol vaginal system)
Delivers 0.15 mg/0.013 mg per day